COPD and Asthma Therapeutics – our new study reveals trends, R&D progress, and predicted revenues Where is the COPD and asthma therapeutics market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead Our 310+ page report provides 370+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing COPD and Asthma Therapeutics Market. See how to exploit the opportunities.
Forecasts to 2030 and other analyses reveal the commercial prospects • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares. • You find original analyses, with business outlooks and developments. • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), product profiles and commercial developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.
By Route of Administration: • Oral • Inhaled • Others
By Point of Sale/Distribution Channel: • Retail pharmacies • Hospital pharmacies • Others
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 4 regional and 10 leading national markets:
By Region:
• North America – U.S. – Canada
• Europe – Germany – France – UK – Italy – Spain – Rest of Europe
• Asia Pacific – China – Japan – India – Rest of APAC
• Rest of the World
The report also includes profiles and for some of the leading companies in the COPD and asthma therapeutics Market, with a focus on this segment of these companies’ operations.
There will be growth in both established and in developing countries. Our analyses show that the both developed and developing markets, U.S., Germany, UK and Japan, China in particular, will continue to achieve high revenue growth to 2030.
Leading companies and the potential for market growth Overall world revenue for COPD and Asthma Therapeutics Market will surpass US$ xx million in 2020, our work calculates. We predict strong revenue growth through to 2030.
Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How the COPD and Asthma Therapeutics Market report helps you In summary, our 310+ page report provides you with the following knowledge:
• Revenue forecasts to 2030 for COPD and Asthma Therapeutics Market, with forecasts for Treatment, Route of Administration, and Distribution Channel, each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues
• Revenue forecasts to 2030 for 4 regional and 10 key national markets – See forecasts for the COPD and Asthma Therapeutics market in North America, Europe, Asia-Pacific and Rest of the World. Also forecasted is the market in the US, Canada, Germany, France, UK, Italy, Spain, China, India, and Japan.
• Prospects for established firms and those seeking to enter the market– including company profiles for 12 of the major companies involved in the COPD and Asthma Therapeutics Market. Some of the company’s profiles in this report include AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Merck, F. Hoffmann-La Roche AG.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the COPD and Asthma Therapeutics Market and leading companies. You will find data, trends and predictions.
Buy our report today Asthma & COPD Therapies Market Report 2020-2030: Forecasts by Treatment (Bronchodilator Monotherapy (Anticholinergics (Spiriva, Atrovent, Eklira, Others), SABA (Ventolin, ProAir, Proventil, Xoponex, Others), LABA (Foradil, Arcapta/Onbrez, Brovana, Serevent, Others)), (Anti-Inflammatory Drugs (Corticosteroids (Pulmicort, Flixotide, QVAR, Asmanex, Others), Anti-Leukotrienes (Singulair, Others), Monoclonal Antibodies (Xolair, Cinqair, Nucala, Benralizumab, Lebrikizumab, Dupilumab)), Others, (Combination Drugs (Advair, Symbicort, Combivent, Dulera, Relvar/Breo, Others)), by Route of Administration (Oral, Inhaled, Others), by Point of Sale/Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Others), Geography (North America, Europe, Asia Pacific, Rest of the World) PLUS COVID-19 Impact Scenarios and Profiles of Leading Asthma & COPD Companies. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Global COPD and Asthma Therapies Market 2020-2030 1.1 Introduction 1.2 Why You Should Read This Report 1.3 What This Report Delivers 1.4 Key Questions Answered by This Analytical Report Include: 1.5 Who is This Report For? 1.6 Methodology 1.7 Frequently Asked Questions (FAQs) 1.8 Associated Visiongain Reports 1.9 About Visiongain
2 Executive Summary
3 Introduction to the COPD and Asthma Therapies Market 3.1 Introduction to the COPD and Asthma Therapies 3.2 The Pharmaceutical Industry: A Very Brief Overview 3.3 What is Asthma? 3.3.1 Trends in Asthma Prevalence 3.3.2 Pathophysiology of Asthma 3.3.3 Symptoms of Asthma 3.3.4 Causes and Triggers for Asthma 3.3.5 Treatment of Asthma 3.3.6 Drug Delivery Methods in Asthma 3.4 What is Chronic Obstructive Pulmonary Disease (COPD)? 3.4.1 Trends in COPD Prevalence 3.4.2 Pathophysiology of COPD 3.4.3 Signs and Symptoms of COPD 3.4.4 Treatment of COPD 3.4.5 Drug Treatments for COPD 3.4.6 Guidelines for COPD Treatment 3.5 Major Drug Classes in the Treatment of Asthma and COPD 3.5.1 Bronchodilators 3.5.1.1 Beta2-Agonists 3.5.1.2 Anticholinergics 3.5.2 Anti-Inflammatory Drugs 3.5.2.1 Corticosteroids 3.5.2.2 Leukotriene Receptor Antagonists 3.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease 3.5.3 Combination Drugs
4 Industry Insights 4.1 Market Drivers 4.1.1 Increasing prevalence of respiratory diseases on account of increasing pollution 4.1.2 Reducing social stigma asthma and COPD 4.1.3 Strong pipeline for asthma drugs 4.2 Market Restraints/Challenges 4.3 Market Opportunities 4.3.1 Telehealth 4.4 Porter’s five forces 4.4.1 Bargaining Power of Buyers 4.4.2 Bargaining Power of Suppliers 4.4.3 Threat of Substitutes 4.4.4 Threat of New Entrants 4.4.5 Industry Rivalry 4.5 SWOT Analysis 4.5.1 Strength 4.5.1.1 Increasing Prevalence and Disease Burden 4.5.1.2 Advanced Inhaler Technologies 4.5.1.3 High Costs of Treatment 4.5.1.4 The Changing Perception of COPD 4.5.1.5 Developments in Diagnostics 4.5.2 Weakness 4.5.2.1 Low awareness levels in low income groups 4.5.2.2 Patent Cliff for Devices 4.5.2.3 Side-Effects of Drug Classes 4.5.2.4 Costing Pressures in both Developed and Emerging Markets 4.5.3 Opportunities 4.5.3.1 Strong R&D 4.5.3.2 Vast pipeline by numerous players 4.5.3.3 Emergence of telehealth 4.5.4 Threats 4.5.4.1 Patent Expiry 4.5.4.2 The WISDOM Trial Could Reduce Steroid Use in COPD
5 Global COPD and Asthma Therapies Market by Treatment 5.1 Medication Submarket Forecast 2020-2030 5.1.1 Anti-inflammatory drugs Submarket Forecast 2020-2030 5.1.1.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 5.1.1.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 5.1.1.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 5.1.1.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 5.1.1.5 Corticosteroids Submarket Forecast 2020-2030 5.1.1.5.1 Pulmicort Submarket Forecast 2020-2030 5.1.1.5.2 Flixotide Submarket Forecast 2020-2030 5.1.1.5.3 QVAR Submarket Forecast 2020-2030 5.1.1.5.4 Asmanex Submarket Forecast 2020-2030 5.1.1.5.5 Others Submarket Forecast 2020-2030 5.1.1.6 Anti-Leukotrienes Submarket Forecast 2020-2030 5.1.1.6.1 Singulair Submarket Forecast 2020-2030 5.1.1.6.2 Others Submarket Forecast 2020-2030 5.1.1.7 Monoclonal Antibodies Submarket Forecast 2020-2030 5.1.1.7.1 Xolair Submarket Forecast 2020-2030 5.1.1.7.2 Cinqair Submarket Forecast 2020-2030 5.1.1.7.3 Nucala Submarket Forecast 2020-2030 5.1.1.7.4 Benralizumab Submarket Forecast 2020-2030 5.1.1.7.5 Lebrikizumab Submarket Forecast 2020-2030 5.1.1.7.6 Dupilumab Submarket Forecast 2020-2030 5.1.2 Bronchodilator Monotherapy Submarket Forecast 2020-2030 5.1.2.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 5.1.2.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 5.1.2.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 5.1.2.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 5.1.2.5 Anticholinergics Submarket Forecast 2020-2030 5.1.2.5.1 Spiriva Submarket Forecast 2020-2030 5.1.2.5.2 Atrovent Submarket Forecast 2020-2030 5.1.2.5.3 Eklira Submarket Forecast 2020-2030 5.1.2.5.4 Others Submarket Forecast 2020-2030 5.1.2.6 SABA Submarket Forecast 2020-2030 5.1.2.6.1 Ventolin Submarket Forecast 2020-2030 5.1.2.6.2 ProAir Submarket Forecast 2020-2030 5.1.2.6.3 Proventil Submarket Forecast 2020-2030 5.1.2.6.4 Xopenex Submarket Forecast 2020-2030 5.1.2.6.5 Others Submarket Forecast 2020-2030 5.1.2.7 LABA Submarket Forecast 2020-2030 5.1.2.7.1 Foradil Submarket Forecast 2020-2030 5.1.2.7.2 Arcapta/Onbrez Submarket Forecast 2020-2030 5.1.2.7.3 Brovana Submarket Forecast 2020-2030 5.1.2.7.4 Serevent Submarket Forecast 2020-2030 5.1.2.7.5 Others Submarket Forecast 2020-2030 5.1.3 Combination Drugs Submarket Forecast 2020-2030 5.1.3.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 5.1.3.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 5.1.3.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 5.1.3.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 5.1.3.5 Advair Submarket Forecast 2020-2030 5.1.3.6 Symbicort Submarket Forecast 2020-2030 5.1.3.7 Combivent Submarket Forecast 2020-2030 5.1.3.8 Dulera Submarket Forecast 2020-2030 5.1.3.9 Relvar/Breo Submarket Forecast 2020-2030 5.1.3.10 Others Submarket Forecast 2020-2030
6 Global COPD and Asthma Therapies Market by Route of administration 6.1 Oral Submarket Forecast 2020-2030 6.1.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 6.1.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 6.1.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 6.1.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 6.2 Inhaled Submarket Forecast 2020-2030 6.2.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 6.2.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 6.2.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 6.2.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 6.3 Others Submarket Forecast 2020-2030 6.3.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 6.3.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 6.3.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 6.3.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
7 Global COPD and Asthma Therapies Market by Point of Sale 7.1 Retail pharmacies Submarket Forecast 2020-2030 7.1.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Retail Pharmacies Segment forecast, 2020 to 2030 7.1.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Retail pharmacies Segment forecast, 2020 to 2030 7.1.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Retail pharmacies Segment forecast, 2020 to 2030 7.1.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Retail pharmacies Segment forecast, 2020 to 2030 7.2 Hospital pharmacies Submarket Forecast 2020-2030 7.2.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030 7.2.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030 7.2.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030 7.2.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital pharmacies Segment forecast, 2020 to 2030 7.3 Others Submarket Forecast 2020-2030 7.3.1 V Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 7.3.2 U Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 7.3.3 W Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 7.3.4 L Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030
8 Regional and Leading National COPD and Asthma Therapies Forecasts 2020-2030 8.1 Global COPD and Asthma Therapies by National Market Share Forecast 2020-2030 9 North America COPD and Asthma Therapies Forecast 2020-2030 9.1.1 North America COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 9.1.2 North America COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 9.1.3 North America COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 9.1.4 North America COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 9.1.5 U.S. COPD and Asthma Therapies Forecast 2020-2030 9.1.5.1 U.S. COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 9.1.5.2 U.S. COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 9.1.5.3 U.S. COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 9.1.5.4 U.S. COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 9.1.6 Canada COPD and Asthma Therapies Forecast 2020-2030 9.1.6.1 Canada COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 9.1.6.2 Canada COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 9.1.6.3 Canada COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 9.1.6.4 Canada COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
10 Europe COPD and Asthma Therapies Forecast 2020-2030 10.1.1 Europe COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 10.1.2 Europe COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 10.1.3 Europe COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 10.1.4 Europe COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 10.1.5 Germany COPD and Asthma Therapies Forecast 2020-2030 10.1.5.1 Germany COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 10.1.5.2 Germany COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 10.1.5.3 Germany COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 10.1.5.4 Germany COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 10.1.6 France COPD and Asthma Therapies Forecast 2020-2030 10.1.6.1 France COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 10.1.6.2 France COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 10.1.6.3 France COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 10.1.6.4 France COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 10.1.7 UK COPD and Asthma Therapies Forecast 2020-2030 10.1.7.1 UK COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 10.1.7.2 UK COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 10.1.7.3 UK COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 10.1.7.4 UK COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 10.1.8 Spain COPD and Asthma Therapies Forecast 2020-2030 10.1.8.1 Spain COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 10.1.8.2 Spain COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 10.1.8.3 Spain COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 10.1.8.4 Spain COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 10.1.9 Italy COPD and Asthma Therapies Forecast 2020-2030 10.1.9.1 Italy COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 10.1.9.2 Italy COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 10.1.9.3 Italy COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 10.1.9.4 Italy COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 10.1.10 Rest of Europe COPD and Asthma Therapies Forecast 2020-2030 10.1.10.1 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 10.1.10.2 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 10.1.10.3 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 10.1.10.4 Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
11 APAC COPD and Asthma Therapies Forecast 2020-2030 11.1.1 APAC COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 11.1.2 APAC COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 11.1.3 APAC COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 11.1.4 APAC COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 11.1.5 China COPD and Asthma Therapies Forecast 2020-2030 11.1.5.1 China COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 11.1.5.2 China COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 11.1.5.3 China COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 11.1.5.4 China COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 11.1.6 Japan COPD and Asthma Therapies Forecast 2020-2030 11.1.6.1 Japan COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 11.1.6.2 Japan COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 11.1.6.3 Japan COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 11.1.6.4 Japan COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 11.1.7 India COPD and Asthma Therapies Forecast 2020-2030 11.1.7.1 India COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 11.1.7.2 India COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 11.1.7.3 India COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 11.1.7.4 India COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery 11.1.8 Rest of APAC COPD and Asthma Therapies Forecast 2020-2030 11.1.8.1 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 11.1.8.2 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 11.1.8.3 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 11.1.8.4 Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
12 Rest of the World COPD and Asthma Therapies Forecast 2020-2030 12.1.1 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery 12.1.2 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery 12.1.3 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery 12.1.4 Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery
13 Leading Companies in the COPD and Asthma Therapies 13.1 How Will Leading Companies’ Market Shares Change to 2030? 13.2 AstraZeneca 13.2.1 AstraZeneca: Company Overview 13.2.2 AstraZeneca: Financials, 2016-2019 13.2.3 Products / Services 13.2.4 Latest developments related to Key Marketed Products 13.2.4.1 Symbicort: Recent Developments 13.2.4.2 Bevespi Aerosphere: Recent Developments 13.2.4.3 Tudorza/ Eklira Genuair: Recent Developments 13.2.4.4 Duaklir: Recent Developments 13.2.4.5 Fasenra: Recent Developments 13.2.4.6 Other Recent Developments 13.2.5 AstraZeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook 13.3 GlaxoSmithKline 13.3.1 GlaxoSmithKline: Company Overview 13.3.2 GlaxoSmithKline: Financials, 2016-2019 13.3.3 Products / Services 13.3.4 Latest developments related to Key Marketed Products 13.3.4.1 Once-daily Trelegy Ellipta: Recent Developments 13.3.4.2 Trelegy Ellipta: Recent Developments 13.3.4.3 Anoro Ellipta: Recent Developments 13.3.4.4 Nucala: Recent Developments 13.3.4.5 Seretide/Advair: Recent Developments 13.3.4.6 Trelegy Ellipta: Recent Developments 13.3.4.7 Breo Ellipta, Advair Diskus and Advair HFA: Recent Developments 13.4 Boehringer Ingelheim 13.4.1 Boehringer Ingelheim: Company Overview 13.4.2 Boehringer Ingelheim: Financials, 2016-2019 13.4.3 Products / Services 13.4.4 Latest developments related to Key Marketed Products 13.4.4.1 Aservo® EquiHaler: Recent Developments 13.4.4.2 Spiolto Respimat: Recent Developments 13.4.4.3 Spiriva Respimat: Recent Developments 13.4.4.4 Ofev: Recent Developments 13.4.4.5 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook 13.5 Teva 13.5.1 Teva: Company Overview 13.5.2 Teva: Financials, 2016-2019 13.5.3 Products / Services 13.5.4 Latest developments related to Key Marketed Products 13.5.4.1 QVAR: Recent Developments 13.5.4.2 QVAR: Recent Developments 13.5.4.3 DuoResp Spiromax: Recent Developments 13.5.4.4 Aerivio Spiromax: Recent Developments 13.6 Merck 13.6.1 Merck: Company Overview 13.6.2 Merck: Financials, 2016-2019 13.6.3 Products / Services 13.6.4 Latest developments related to Key Marketed Products 13.6.4.1 Dulera: Recent Development 13.7 F.Hoffmann-La Roche AG 13.7.1 F. Hoffmann-La Roche AG: Company Overview 13.7.2 F. Hoffmann-La Roche AG: Financials, 2016-2019 13.7.3 Products / Services 13.7.4 Latest developments related to Key Marketed Products 13.7.4.1 Xolair: Recent Developments 13.8 Novartis 13.8.1 Novartis: Company Overview 13.8.2 Novartis: Financials, 2016-2019 13.8.3 Products / Services 13.8.4 Latest developments related to Key Marketed Products 13.8.4.1 Ultibro Breezhaler: Recent Developments 13.8.4.2 Ultibro Breezhaler: Recent Developments 13.8.4.3 Xolair: Recent Developments 13.9 Mundipharma 13.9.1 Mundipharma: Company Overview 13.9.2 Products / Services 13.9.3 Latest developments related to Key Marketed Products 13.9.3.1 Flutiform (fluticasone propionate and formoterol): Recent Developments 13.9.3.2 Company Related Developments 13.10 Cipla 13.10.1 Cipla: Company Overview 13.10.2 Cipla: Financials, 2016-2019 13.10.3 Products / Services 13.10.4 Mergers & Acquisitions (M&A) Activity 13.10.5 Latest developments related to Key Marketed Products 13.10.5.1 Budesonide Inhalation Suspension: Pipeline Developments 13.10.5.2 SynchroBreathe: Pipeline Developments 13.10.6 Cipla Launch Plans for Respiratory Products 13.10.7 Sunovion Pharmaceuticals: Company Overview 13.10.8 Products / Services 13.10.9 Latest developments related to Key Marketed Products 13.10.9.1 SUN-101: Recent Developments 13.10.9.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook 13.10.9.3 Sunovion -Asthma & COPD Market Forecast, 2019-2030 13.11 Pulmatrix 13.11.1 Pulmatrix: Company Overview 13.11.2 Pulmatrix: Financials, 2016-2019 13.11.3 Products / Services 13.11.4 Latest developments related to Key Pipeline Products 13.11.4.1 PUR0200-US: Recent development 13.11.4.2 PUR0200-US: Recent development 13.11.4.3 PUR1900: Recent development 13.12 TFF PHARMACEUTICALS, INC 13.12.1 TFF PHARMACEUTICALS, INC: Company Overview 13.12.2 Products / Services 13.12.3 Latest developments related to the pipeline products 13.12.3.1 TFF TRIPLE COMBINATION: Recent developments 13.13 Respiratorius AB 13.13.1 Respiratorius AB: Company Overview 13.13.2 Products / Services 13.13.3 Latest developments related to the pipeline products 13.13.3.1 Product: Recent developments
List of Figures Figure 1. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 (US $ MILLION, AGR%) Figure 2. GLOBAL COPD AND ASTHMA THERAPIES MARKET SHARE, 2019 Figure 3. SUMMARY OF GINA GUIDANCE FOR ASTHMA TREATMENT, 2019 Figure 4. SUMMARY OF GOLD GUIDANCE FOR COPD TREATMENT, 2019 Figure 5. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 (US $ MILLION, AGR%) Figure 6. MARKET DRIVERS Figure 7. PORTER’S FIVE FORCES Figure 8. COPD AND ASTHMA THERAPIES MARKET BY TREATMENT Figure 9. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 TREATMENT (%) Figure 10. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 TREATMENT (%) Figure 11. GLOBAL MEDICATION REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 12. GLOBAL ANTI-INFLAMMATORY DRUGS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 13. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030 Figure 14. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030 Figure 15. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030 Figure 16. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ANTI-INFLAMMATORY SEGMENT FORECAST, 2020 TO 2030 Figure 17. GLOBAL CORTICOSTEROIDS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 18. GLOBAL PULMICORT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 19. GLOBAL FLIXOTIDE REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 20. GLOBAL QVAR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 21. GLOBAL ASMANEX REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 22. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 23. GLOBAL ANTI-LEUKOTRIENES REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 24. GLOBAL SINGULAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 25. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 26. GLOBAL MONOCLONAL ANTIBODIES REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 27. GLOBAL XOLAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 28. GLOBAL CINQAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 29. GLOBAL NUCALA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 30. GLOBAL BENRALIZUMAB REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 31. GLOBAL LEBRIKIZUMAB REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 32. GLOBAL DUPILUMAB REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 33. GLOBAL BRONCHODILATOR MONOTHERAPY REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 34. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030 Figure 35. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030 Figure 36. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030 Figure 37. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR BRONCHODILATOR MONOTHERAPY SEGMENT FORECAST, 2020 TO 2030 Figure 38. GLOBAL ANTICHOLINERGICS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 39. GLOBAL SPIRIVA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 40. GLOBAL ATROVENT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 41. GLOBAL EKLIRA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 42. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 43. GLOBAL SABA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 44. GLOBAL VENTOLIN REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 45. GLOBAL PROAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 46. GLOBAL PROVENTIL REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 47. GLOBAL XOPENEX REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 48. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 49. GLOBAL LABA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 50. GLOBAL FORADIL REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 51. GLOBAL ARCAPTA/ONBREZ REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 52. GLOBAL BROVANA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 53. GLOBAL SEREVENT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 54. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 55. GLOBAL COMBINATION DRUGS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 56. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030 Figure 57. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030 Figure 58. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030 Figure 59. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR COMBINATION DRUGS SEGMENT FORECAST, 2020 TO 2030 Figure 60. GLOBAL ADVAIR REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 61. GLOBAL SYMBICORT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 62. GLOBAL COMBIVENT REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 63. GLOBAL DULERA REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 64. GLOBAL RELVAR/BREO REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 65. GLOBAL OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 66. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 ROUTE OF ADMINISTRATION (%) Figure 67. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 DISTRIBUTION CHANNEL (%) Figure 68. ORAL REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 69. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ORAL SEGMENT FORECAST, 2020 TO 2030 Figure 70. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ORAL SEGMENT FORECAST, 2020 TO 2030 Figure 71. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ORAL SEGMENT FORECAST, 2020 TO 2030 Figure 72. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR ORAL SEGMENT FORECAST, 2020 TO 2030 Figure 73. INHALED PHARMACIES REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 74. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR INHALED SEGMENT FORECAST, 2020 TO 2030 Figure 75. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR INHALED SEGMENT FORECAST, 2020 TO 2030 Figure 76. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR INHALED SEGMENT FORECAST, 2020 TO 2030 Figure 77. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR INHALED SEGMENT FORECAST, 2020 TO 2030 Figure 78. OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 79. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 80. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 81. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 82. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 83. COPD AND ASTHMA THERAPIES MARKET BY POINT OF SALE Figure 84. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 POINT OF SALE (%) Figure 85. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 POINT OF SALE (%) Figure 86. RETAIL PHARMACIES REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 87. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR RETAIL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 88. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR RETAIL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 89. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR RETAIL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 90. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR RETAIL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 91. HOSPITAL PHARMACIES REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 92. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR HOSPITAL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 93. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR HOSPITAL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 94. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR HOSPITAL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 95. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR HOSPITAL PHARMACIES SEGMENT FORECAST, 2020 TO 2030 Figure 96. OTHERS REVENUE FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 97. V SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 98. U SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 99. W SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 100. L SHAPED RECOVERY: GLOBAL COPD AND ASTHMA THERAPIES MARKET FOR OTHERS SEGMENT FORECAST, 2020 TO 2030 Figure 101. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 (%) Figure 102. NORTH AMERICA COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 103. NORTH AMERICA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 104. NORTH AMERICA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 105. NORTH AMERICA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 106. NORTH AMERICA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 107. U.S. AIR QUALITY MAP Figure 108. U.S. COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 109. U.S. COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 110. U.S. COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 111. U.S. COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 112. U.S. COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 113. PREVALENCE OF DIAGNOSED COPD AMONG CANADIANS AGED 35 YEARS AND OLDER, BY AGE GROUP AND SEX, CANADA Figure 114. CANADA COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 115. CANADA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 116. CANADA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 117. CANADA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 118. CANADA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 119. EUROPE COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 120. EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 121. EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 122. EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 123. EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 124. GERMANY COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 125. GERMANY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 126. GERMANY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 127. GERMANY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 128. GERMANY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 129. FRANCE COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 130. FRANCE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 131. FRANCE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 132. FRANCE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 133. FRANCE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 134. UK COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 135. UK COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 136. UK COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 137. UK COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 138. UK COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 139. SPAIN COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 140. SPAIN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 141. SPAIN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 142. SPAIN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 143. SPAIN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 144. ITALY COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 145. ITALY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 146. ITALY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 147. ITALY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 148. ITALY COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 149. REST OF EUROPE COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 150. REST OF EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 151. REST OF EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 152. REST OF EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 153. REST OF EUROPE COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 154. APAC COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 155. APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 156. APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 157. APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 158. APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 159. CHINA COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 160. CHINA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 161. CHINA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 162. CHINA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 163. CHINA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 164. JAPAN COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 165. JAPAN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 166. JAPAN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 167. JAPAN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 168. JAPAN COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 169. INDIA COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 170. INDIA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 171. INDIA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 172. INDIA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 173. INDIA COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 174. REST OF APAC COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 175. REST OF APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 176. REST OF APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 177. REST OF APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 178. REST OF APAC COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 179. REST OF THE WORLD COPD AND ASTHMA THERAPIES FORECAST 2020-2030 (US$ MILLION, AGR %) Figure 180. REST OF THE WORLD COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, V SHAPED RECOVERY Figure 181. REST OF THE WORLD COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, U SHAPED RECOVERY Figure 182. REST OF THE WORLD COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, W SHAPED RECOVERY Figure 183. REST OF THE WORLD COPD AND ASTHMA THERAPIES MARKET: REVENUE FORECAST, L SHAPED RECOVERY Figure 184. LEADING ASTHMA & COPD DRUG MANUFACTURERS: REVENUE ($BN), 2019 Figure 185. LEADING ASTHMA & COPD DRUG MANUFACTURERS: MARKET SHARE (%), 2019 Figure 186. LEADING ASTHMA & COPD DRUG MANUFACTURERS: MARKET FORECAST (%), 2030 Figure 187. ASTRAZENECA: FINANCIALS, 2016-2019 Figure 188. GLAXOSMITHKLINE: FINANCIALS, 2016-2019 Figure 189. PRODUCTS / SERVICES Figure 190. BOEHRINGER INGELHEIM: FINANCIALS, 2016-2019 Figure 191. TEVA: FINANCIALS, 2016-2019 Figure 192. MERCK: FINANCIALS, 2016-2019 Figure 193. F. HOFFMANN-LA ROCHE AG: FINANCIALS, 2016-2019 Figure 194. NOVARTIS: FINANCIALS, 2016-2019 Figure 195. CIPLA: FINANCIALS, 2016-2019 Figure 196. PULMATRIX: FINANCIALS, 2016-2019 Figure 197. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 TREATMENT (%) Figure 198. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 ROUTE OF ADMINISTRATION (%) Figure 199. GLOBAL COPD AND ASTHMA THERAPIES REVENUE FORECAST 2020-2030 POINT OF SALE (%)
List of Tables Table 1. Executive Summary Table 2. Global COPD and Asthma Therapies Revenue Forecast 2020-2030 (US $ million, AGR %, CAGR%) Table 3. Key Factors Affecting the Bargaining Power of Buyer Table 4. Key Factors Affecting the Bargaining Power of Suppliers Table 5. Key Factors Affecting the Threat of Substitutes Table 6. Key Factors Affecting the Threat of New Entrants Table 7. Key Factors Affecting the Industry Rivalry Table 8. Global COPD and Asthma Therapies Revenue Forecast 2020-2030 Treatment (US$ million, AGR %) Table 9. Global Medication Revenue Forecast 2020-2030 (US$ million, AGR %) Table 10. Global COPD and Asthma Therapies Revenue Forecast 2020-2030 Anti- Inflammatory Drugs (US$ million, AGR %) Table 11. V Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 Table 12. U Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 Table 13. W Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 Table 14. L Shaped Recovery: Global COPD and Asthma Therapies Market for Anti-Inflammatory Segment forecast, 2020 to 2030 Table 15. Global Corticosteroids Revenue Forecast 2020-2030 (US$ million, AGR %) Table 16. Global Pulmicort Revenue Forecast 2020-2030 (US$ million, AGR %) Table 17. Global Flixotide Revenue Forecast 2020-2030 (US$ million, AGR %) Table 18. Global QVAR Revenue Forecast 2020-2030 (US$ million, AGR %) Table 19. Global Asmanex Revenue Forecast 2020-2030 (US$ million, AGR %) Table 20. Global Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 21. Global Anti-Leukotrienes Revenue Forecast 2020-2030 (US$ million, AGR %) Table 22. Global Singulair Revenue Forecast 2020-2030 (US$ million, AGR %) Table 23. Global Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 24. Global Monoclonal Antibodies Revenue Forecast 2020-2030 (US$ million, AGR %) Table 25. Global Xolair Revenue Forecast 2020-2030 (US$ million, AGR %) Table 26. Global Cinqair Revenue Forecast 2020-2030 (US$ million, AGR %) Table 27. Global Nucala Revenue Forecast 2020-2030 (US$ million, AGR %) Table 28. Global Benralizumab Revenue Forecast 2020-2030 (US$ million, AGR %) Table 29. Global Lebrikizumab Revenue Forecast 2020-2030 (US$ million, AGR %) Table 30. Global Dupilumab Revenue Forecast 2020-2030 (US$ million, AGR %) Table 31. Global Bronchodilator Monotherapy Revenue Forecast 2020-2030 (US$ million, AGR %) Table 32. V Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 Table 33. U Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 Table 34. W Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 Table 35. L Shaped Recovery: Global COPD and Asthma Therapies Market for Bronchodilator Monotherapy Segment forecast, 2020 to 2030 Table 36. Global Anticholinergics Revenue Forecast 2020-2030 (US$ million, AGR %) Table 37. Global Spiriva Revenue Forecast 2020-2030 (US$ million, AGR %) Table 38. Global Atrovent Revenue Forecast 2020-2030 (US$ million, AGR %) Table 39. Global Eklira Revenue Forecast 2020-2030 (US$ million, AGR %) Table 40. Global Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 41. Global SABA Revenue Forecast 2020-2030 (US$ million, AGR %) Table 42. Global Ventolin Revenue Forecast 2020-2030 (US$ million, AGR %) Table 43. Global ProAir Revenue Forecast 2020-2030 (US$ million, AGR %) Table 44. Global Proventil Revenue Forecast 2020-2030 (US$ million, AGR %) Table 45. Global Xopenex Revenue Forecast 2020-2030 (US$ million, AGR %) Table 46. Global Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 47. Global LABA Revenue Forecast 2020-2030 (US$ million, AGR %) Table 48. Global Foradil Revenue Forecast 2020-2030 (US$ million, AGR %) Table 49. Global Arcapta/Onbrez Revenue Forecast 2020-2030 (US$ million, AGR %) Table 50. Global Brovana Revenue Forecast 2020-2030 (US$ million, AGR %) Table 51. Global Serevent Revenue Forecast 2020-2030 (US$ million, AGR %) Table 52. Global Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 53. Global Combination Drugs Revenue Forecast 2020-2030 (US$ million, AGR %) Table 54. V Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 Table 55. U Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 Table 56. W Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 Table 57. L Shaped Recovery: Global COPD and Asthma Therapies Market for Combination Drugs Segment forecast, 2020 to 2030 Table 58. Global Advair Revenue Forecast 2020-2030 (US$ million, AGR %) Table 59. Global Symbicort Revenue Forecast 2020-2030 (US$ million, AGR %) Table 60. Global Combivent Revenue Forecast 2020-2030 (US$ million, AGR %) Table 61. Global Dulera Revenue Forecast 2020-2030 (US$ million, AGR %) Table 62. Global Relvar/Breo Revenue Forecast 2020-2030 (US$ million, AGR %) Table 63. Global Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 64. Global COPD and Asthma Therapies Revenue Forecast 2020-2030 Distribution Channel (US$ million, AGR %) Table 65. Oral Revenue Forecast 2020-2030 (US$ million, AGR %) Table 66. V Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 Table 67. U Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 Table 68. W Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 Table 69. L Shaped Recovery: Global COPD and Asthma Therapies Market for Oral Segment forecast, 2020 to 2030 Table 70. Inhaled Revenue Forecast 2020-2030 (US$ million, AGR %) Table 71. V Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 Table 72. U Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 Table 73. W Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 Table 74. L Shaped Recovery: Global COPD and Asthma Therapies Market for Inhaled Segment forecast, 2020 to 2030 Table 75. Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 76. V Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 77. U Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 78. W Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 79. L Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 80. Global COPD and Asthma Therapies Revenue Forecast 2020-2030 Distribution Channel (US$ million, AGR %) Table 81. Retail pharmacies Revenue Forecast 2020-2030 (US$ million, AGR %) Table 82. V Shaped Recovery: Global COPD and Asthma Therapies Market for Retail Pharmacies Segment forecast, 2020 to 2030 Table 83. U Shaped Recovery: Global COPD and Asthma Therapies Market for Retail Pharmacies Segment forecast, 2020 to 2030 Table 84. W Shaped Recovery: Global COPD and Asthma Therapies Market for Retail Pharmacies Segment forecast, 2020 to 2030 Table 85. L Shaped Recovery: Global COPD and Asthma Therapies Market for Retail Pharmacies Segment forecast, 2020 to 2030 Table 86. Hospital pharmacies Revenue Forecast 2020-2030 (US$ million, AGR %) Table 87. V Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital Pharmacies Segment forecast, 2020 to 2030 Table 88. U Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital Pharmacies Segment forecast, 2020 to 2030 Table 89. W Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital Pharmacies Segment forecast, 2020 to 2030 Table 90. L Shaped Recovery: Global COPD and Asthma Therapies Market for Hospital Pharmacies Segment forecast, 2020 to 2030 Table 91. Others Revenue Forecast 2020-2030 (US$ million, AGR %) Table 92. V Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 93. U Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 94. W Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 95. L Shaped Recovery: Global COPD and Asthma Therapies Market for Others Segment forecast, 2020 to 2030 Table 96. Global COPD and Asthma Therapies Revenue Forecast 2020-2030 Region (US$ million, AGR %) Table 97. North America COPD and ASTHMA Prevalence Table 98. North America COPD and ASTHMA Therapies Revenue Forecast 2020-2030 Treatment (US$ million, AGR %) Table 99. North America COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 100. North America COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 101. North America COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 102. North America COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 103. U.S. COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 104. U.S. COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 105. U.S. COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 106. U.S. COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 107. U.S. COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 108. Canada COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 109. Canada COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 110. Canada COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 111. Canada COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 112. Canada COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 113. Europe COPD and ASTHMA Therapies Revenue Forecast 2020-2030 Treatment (US$ million, AGR %) Table 114. Europe COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 115. Europe COPD and Asthma Therapies Market: Revenue Forecast, u Shaped Recovery Table 116. Europe COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 117. Europe COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 118. Germany COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 119. Germany COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 120. Germany COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 121. Germany COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 122. Germany COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 123. France COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 124. France COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 125. France COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 126. France COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 127. France COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 128. UK COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 129. UK COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 130. UK COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 131. UK COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 132. UK COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 133. Spain COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 134. Spain COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 135. Spain COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 136. Spain COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 137. Spain COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 138. Italy COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 139. Italy COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 140. Italy COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 141. Italy COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 142. Italy COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 143. Rest of Europe COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 144. Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 145. Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 146. Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 147. Rest of Europe COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 148. APAC COPD and ASTHMA Therapies Revenue Forecast 2020-2030 Treatment (US$ million, AGR %) Table 149. APAC COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 150. APAC COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 151. APAC COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 152. APAC COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 153. China COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 154. China COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 155. China COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 156. China COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 157. China COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 158. Japan COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 159. Japan COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 160. Japan COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 161. Japan COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 162. Japan COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 163. India COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 164. India COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 165. India COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 166. India COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 167. India COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 168. Rest of APAC COPD and Asthma Therapies Forecast 2020-2030 (US$ million, AGR %) Table 169. Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 170. Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 171. Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 172. Rest of APAC COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 173. Rest of the World COPD and ASTHMA Therapies Revenue Forecast 2020-2030 Treatment (US$ million, AGR %) Table 174. Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, V Shaped Recovery Table 175. Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, U Shaped Recovery Table 176. Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, W Shaped Recovery Table 177. Rest of the World COPD and Asthma Therapies Market: Revenue Forecast, L Shaped Recovery Table 178. Leading Companies in Asthma & COPD diseases
AstraZeneca Boehringer Ingelheim Cipla F.Hoffmann-La Roche AG GlaxoSmithKline Merck Mundipharma Novartis Pulmatrix Respiratorius AB Teva TFF PHARMACEUTICALS, INC
List of Organizations Mentioned in the Report American Lung Association Asthma & Bronchitis Association of India Asthma and Allergy Foundation of America Asthma Society of India Asthma.com European Federation of Allergy and Airway Diseases European Federation of Allergy and Airways Diseases European Lung Foundation European Respiratory Society European Respiratory Society National Heart, Lung, and Blood Institute The American Academy of Allergy, Asthma & Immunology The Asthma UK and British Lung Foundation Partnership World Health Organization
Download sample pages
Complete the form below to download your free sample pages for Asthma & COPD Therapies Market Report 2020-2030
Fierce competition, stringent regulations, diminishing research and development, shrinking margins, strong price pressures and patent cliffs encompass today’s drug industry.
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
Visiongain Publishes Regenerative Medicine Market Report 2023-2033
The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
